# Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

> **NCT04350164** · — · COMPLETED · sponsor: **Federal Research Institute of Pediatric Hematology, Oncology and Immunology** · enrollment: 67 (actual)

## Conditions studied

- Wiskott-Aldrich Syndrome

## Interventions

- **DRUG:** Romiplostim

## Key facts

- **NCT ID:** NCT04350164
- **Lead sponsor:** Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-01
- **Primary completion:** 2019-12-27
- **Final completion:** 2020-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2020-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04350164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04350164, "Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04350164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*